Regenerative Medicine – MaRS Industry Report 2008

by Alexey Bersenev on April 26, 2008 · 2 comments

in business

Readers, if you have some amount of money (I doubt it, but anyway) and thinking where to invest, read this or just read this post.

Recent RegenMed Industry report, published by Canadian MaRS Venture Group in December 2007, available now on MaRS blog.

After 30 years of research, many regenerative medicine technologies are in development and approaching commercialization.
The main force driving the growth of the regenerative medicine market is both compelling and well known: demographic trends are putting pressure on healthcare. The U.S. alone spent an estimated $2.2T, or 16% of GDP, on healthcare in 2006 – a number that is expected to reach $4.1T by 2016. In this context, it is not surprising that the current market for regenerative medicines is $3.6B and growing. Conservative estimates suggest that the global market for regenerative medicine will reach between $11.5B to $20B by 2010 with a projected CAGR of 27.5%. U.S. sales of commercially available stem cell therapies alone were already $10M in the first half of 2007.

I like this model from the Report:


Very good analysis of perspectives!
You can download it for free after registration.

Regenerative Medicine Report 2008

{ 2 comments… read them below or add one }

jrowley May 24, 2008 at 9:43 am

This is a great resource, thanks for posting! The hybrid business model is an interesting way to look at cell therapy – in between devices and small molecules.

Other really good content has been aggregated at Chris Mason’s website: http://www.chrismason.com

check out his ‘general publications’ which include many of his editorials on the field (highly recommended) as well as the ‘Industrial Library and Links’ for many useful documents.

Reply

Alex May 30, 2008 at 4:26 am

thank you for link to the Chris Manson web-site,
I just realize how many useful literature we can find there! Very good business reviews!

Reply

Cancel reply

Leave a Comment

Previous post:

Next post: